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| INTRODUCTION
Current treatment for hemophilia A involves administration of factor concentrates to prevent or treat bleeds. Although replacement of FVIII has improved life expectancy and quality, limitations include frequent infusions at high costs and the risk of inhibitor formation. 1, 2 Gene therapy is a potential alternative long-term treatment option that works by producing endogenous FVIII following a single intravenous infusion of a vector containing the appropriate genetic code that has trophism for the liver. 3 This enables the liver to produce relevant factor and even modest increases (plasma level of 2 ng/mL resulting in an increase in activity of 1%) can ameliorate severe forms of the disease. 4 To date, gene therapy has been successfully used to treat hemophilia B [5] [6] [7] [8] [9] and recently successful gene transfer has been reported in hemophilia A.
10
The adeno-associated virus (AAV) serves as a promising gene delivery system as it can transduce dividing and non-dividing cells and has not been associated with any disease. [11] [12] [13] Adeno-associated viruses are small, non-enveloped single stranded, DNA viruses belonging to the Parvoviridae family and Dependovirus genus that cannot replicate autonomously and require a helper virus such as herpes simplex or adeno virus. 14 Preexisting immunity against AAV vectors may represent a major barrier in gene transfer which could potentially result in clearance of the vector before it reaches the target cell. 9, 15 The impact of preexisting immunity suggests that screening patients for seroprevalence may help identify those most likely to benefit from gene transfer.
Seroprevalence to different AAV serotypes is measured by either: (a) total antibody binding to the AAV capsid via immunoassay, or (b) detection of inhibitors that neutralize in vitro and in vivo the ability of AAV vectors to transduce. 16 Immunoassay is a capturebased method to detect antibodies capable of binding to the AAV capsid. The AAV capsid or peptide is coated on a plate, plasma or serum added, and antibodies detected with a secondary reagent.
17
In vitro cell-based assays use a reporter AAV vector that is incubated with the test sample before transduction of a cell line. These are amongst the most widely used methods of determining anti-AAV neutralizing factors and the transduction inhibition assay is considered a standard.
18
With the clinical application of gene therapy using AAV5 and AAV8
in hemophilia, 7, 19 this study aimed to measure the prevalence of these serotypes using assays that measure transduction inhibition and total antibody level in the UK hemophilia A population. Secondary aims included measuring differences in the prevalence of AAV5 and AAV8 in those who were exposed to plasma derived products and those who were not. Furthermore, differences in seroprevalence of AAV5 and AAV8 based on human immunodeficiency virus (HIV) and hepatitis C status as well as exposure were also assessed.
| MATERIALS AND METHODS
Plasma samples from a total of 101 hemophilia A patients recruited from seven UK hemophilia centers were tested for preexisting neutralizing factors to AAV5 and AAV8 using transduction inhibition (TI) activity and total antibody assay (TAb). 
| AAV5 and AAV8 total antibodies assay for human plasma
Total antibodies against AAV5 were measured in human plasma using a validated sequential bridging electrochemiluminescence (ECL) assay on the MSD platform as described previously. 
Essentials
• Gene therapy is a potential long-term treatment for hemophilia A.
• Hemophilia A patients were recruited in the UK and tested for preexisting immunity to AAV5 and AAV8.
• 21% of patients had antibodies against AAV5 and 23% had antibodies against AAV8.
• 25% of patients had inhibitors to AAV5 and 38% of patients had inhibitors to AAV8.
Conclusions: Screening for preexisting immunity may be important in identifying patients most likely to benefit from gene therapy. Clinical studies may be needed to evaluate the impact of preexisting immunity on the safety and efficacy of AAV mediated gene therapy.
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BioMarin Pharmaceutical were determined as the reciprocal dilution of plasma samples at the titer cut point, S/N = 1.30. Average sensitivity for measuring antibodies to AAV5 was 4.5 ng/mL.
Total IgG antibodies to AAV8 were measured using a previously published ELISA technique. 18 All samples with a mean optical density of >0.506 were considered and results reported as the reciprocal titer at the cut point. As there are no human anti-AAV8 monoclonal antibodies available, the AAV8 limit of detection was determined to be 18.8 μg/mL using human intravenous immunoglobulins (IVIg) solution.
| Cell-based AAV5 and AAV8 transduction inhibition titer assay for human plasma
A validated AAV5 TI assay for human plasma samples has been previously described. 20 AAV5 TI titers were determined as the reciprocal dilution of plasma samples at the titer cut point, 44 .9% transduction of the negative control. The method used to measure the neutralising effect of AAV8 has also been previously described.
18 AAV8 TI titers were determined as the first reciprocal dilution at which >38.4% inhibition of transduction by comparison with the negative control.
| Statistical analysis
Continuous variables are presented as median and interquartile range (IQR) and categorical data as frequency and percentages. To evaluate differences between groups, Pearsons's chi-square test was used when the expected cell frequencies were equal to or greater than 5 and Fisher's exact test was used when the expected numbers were less than 5. Univariate analysis was performed to identify significant variables and those significant were used in the multivariate logistic regression analysis to identify the independent predictive variables. P values (two-tailed) <0.050 was considered statistically significant. Data were analyzed using SPSS version 23
(IBM, Armonk, New York).
| RESULTS
Of the 101 patients recruited, one was excluded as the patient was not previously treated with FVIII. Results were analysed for 100 patients and descriptive characteristics of the population are presented in Table 1 .
The number of positive and negative patients for AAV5 and AAV8 based on the TI and TAb assays are presented in Table 2 . In this study, positivity in either or both assays were used as a measure of seroprevalence. Seropositivity using TI and TAb assays are presented in Table 3 .
In patients positive for AAV5 the TI assay titers ranged from <2 to were assessed, results were available for all 100 patients and are presented in Table 4 . Mutlivariate analysis of increasing age and seroprevalence of both AAV5 and AAV8 are presented in Table 5 .
| DISCUSSION
In the present study, patient samples were tested for inhibitors of transduction and total antibodies for AAV5 and 8. We found that 21% of patients had antibodies to AAV5 and 23% of patients had antibodies to AAV8. Twenty-five percent of patients exhibited inhibitors to AAV5 transduction and 38% of patients had inhibitors of AAV8 transduction. Thirty percent of patients were positive in either assay for AAV5 and 40% for AAV8. Fifteen percent had antibodies against both AAV5 and AAV8, 23% had inhibitors against both capsids, and 24%
were positive in both assays for both AAV5 and AAV8.
Previous studies on AAV seroprevalence have indicated that following exposure there is production of antibodies against AAV from all four IgG subclasses which harbor neutralizing properties but other unidentified factors within individuals may also be present. Therefore, current estimates of seroprevalence encompass measures of antibodies against AAV or other neutralizing factors (Table 6 ). TAb titers of AAV5 and AAV8 confirming the existence of cross reactivity which has been observed in previous studies.
21

TA B L E 1 Demographics of the hemophilia A cohort
Median (IQR)
21,44
TA B L E 3 Comparison (%) between the transduction inhibition and total antibodies assays for AAV5 and AAV8 there is a lack of standardization of assays that measure neutralizing activity and total antibodies, therefore there is a variation in cutoff titer values where participants are considered positive. Previous studies set the cut-off positive titer at ≥50%, 21, 26, 45 which was higher than the positive cut-off values set in this study, and may influence the results. It is also important to note that for previous studies 26, 28, 29 the cut-off was determined in healthy US donors. In addition, the cutoff threshold for determining seroprevalence may change with geographical location and/or the utilization of patient-specific samples during validation of an assay. It is imperative therefore to standardize measurement of seroprevalence of AAV in hemophilia patients, not only as a single measurement but in a longitudional study as this may impact the eligibility and outcome of gene therapy.
We report a significant increase in seroprevalence of AAV8 in patients exposed to plasma products. There was also a significant increase in seroprevalence of both AAV5 and AAV8 in patients who were exposed to hepatitis C. Further investigation is required to establish the cause of increased seroprevalence due to plasma exposure and hepatitis C. However, transfusion transmitted infection cannot be discounted.
Seroprevalence was higher with increasing age in this study, which has been observed in previously. Evidence from healthy individuals in Japan showed that AAV infection occurred in childhood and seropositivity subsequently decreased, however there was a second increase of seropositivity after 30 years of age. 46 Similarly, another Japanese study of healthy as well as hemophilia patients observed an increase in seropositivity with age. 
| Limitations
As discussed previously, various factors influence the sensitivity of assays for measuring TAb and TI to AAV and these need to 
| CONCLUSION
Despite progression in the current treatment of hemophilia A from plasma derived to recombinant products, natural exposure to AAV occurs at an early age, as shown in seroprevalence studies in both healthy and paediatric hemophilia populations. 20, 26, 43 Therefore, screening may need to be considered for those most likely to respond to gene therapy with AAV vectors. It is currently unknown whether some level of seropositivity to AAV may be tolerated and clinical studies will need to evaluate the effect of preexisting immunity on the safety and efficacy of AAV mediated gene therapy.
Further investigation is required to explore the link between increased seroprevalence in patients exposed to plasma products and Hepatitis C.
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